Updates are available Correction dated 2025-04-01

Article History

Accepted: 15 February 2025

First Online: 6 March 2025

Change Date: 3 April 2025

Change Type: Update

Change Details: In this article, the author’s name Margaret von Mehren was incorrectly written as Margaret von Meren.

Change Date: 1 April 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s11864-025-01315-7

Declarations

:

: Demitrios Dedousis has served as a personal consultant for Exelixis. Elyse Gadra has declared that she has no conflicts of interest. Joseph Van Galen has received the Fox Chase Cancer Center Trainee Research Grant, royalties from the NIH Technology Transfer office, payment for lectures at Exelixis and Plexus Communications, and support for attending the 2024 National Comprehensive Cancer Network’s annual meeting. Margaret von Mehren declares that Fox Chase Cancer Center received support for Phase II Efficacy Study of Temozolomide in Advanced Succinate Dehydrogenase-Mutant/Deficient Gastrointestinal Stromal Tumor, which is discussed in this manuscript. Margaret von Mehren also declares that she sits as the Chair of the NCCN Soft Tissue Sarcoma Panel and the Co-Chair of Mentoring Committee for the Connective Tissue Oncology Society.

: This article does not contain any studies with human or animal subjects performed by any of the authors.